Purpose: To investigate potential cytotoxic 
INTRODUCTION
CTLA-4 signaling is well-documented in its ability to downregulate T-cell proliferation and cytokine production [1, 2] . Studies using CTLA-4 antibodies have shown that CTLA-4 blocks T-cell proliferation, IL-2 production and NFAT translocation into the nucleus, implying that its general effects downplay the immune response [3] . An in vivo study of CTLA-4 knockout mice had tissue destruction by the immune system and extensive lymphadenopathy [4] .
The full activation of naïve T-cells depends on two signals that ignite proliferation, differentiation and cytokine secretion [2] . The first is provided by the T-cell receptor (TcR) upon recognition of a specific antigenic peptide in complex with a MHC class II molecule. The second signal is delivered by the T-cell's co-stimulatory receptors upon ligation of their counterparts by antigen presenting cells (APC). The balance between signaling of the major co-stimulatory molecules CD28 (the positive co-receptor) and CTLA-4 (the negative co-receptor) determines the outcome of immune response [5] .
Transmembrane adaptor proteins (TRAPS) facilitate precise signal transduction by forming specific protein complexes [5] . Unlike kinases, which use enzymatic and transcriptional activity to promote signaling, TRAPS act as scaffolds and recruit molecules for detailed intracellular signaling complexes [6] . Recently, our laboratory found that a small TRAP, SIT, binds to CTLA-4 and enhances CTLA-4 surface expression [6] . SIT is a disulfide-linked homodimeric polypeptide which is exclusively expressed in lymphocytes. In contrast to the other transmembrane adaptor proteins known so far, SIT is a heavily glycosylated polypeptide [13] . This could indicate that SIT possesses an external ligand that modulates its function. This study was conducted to understand the molecular mechanisms leading to tyrosine phosphorylation of CTLA4/SIT complex.
EXPERIMENTAL Cells and reagents
Jurkat T-cells (ATCC, American Type Culture Collection, VA, USA ) were cultured in RPMI 1640 supplemented with 5 % fetal calf serum (FCS), 2 mM L-glutamine and 100 U/ml penicillin/streptomycin [7] . Anti-CD3 (OKT3) was obtained from the ATCC and anti-human CTLA-4 mAb was provided by Dr. Broeker (Greifswald, Germany). Anti-HA antibody was purchased from Covance Research Product Inc.
Plasmid DNA cloning
Full-length human SIT-R cDNA PCR primer sequences were 5-gctctagagccaccatg-3 sense and 5-tgacacgccaagcttggtac-3 antisense. PCR contained five cycles of 60 s at 94 ºC, 30 s at 37 ºC and 60 s at 72 ºC and a further 25 cycles within an annealing temperature of 45 ºC. The amplified products were ligated into the TA cloning vector (Invitrogen) and confirmed by DNA sequencing.
Immunoprecipitation and immunoblotting
Cells were lysed in an ice-cold lysis buffer containing 1 % Triton X-100 in 20 mM Tris-HCl, pH 8.3, 150 mM NaCl, protease inhibitors, and phosphatase inhibitors. Post-nuclear lysates were incubated for 1 h with the indicated antibody. Protein A-Sepharose beads (30 µl, Amersham Pharmacia) were added and incubated for 1 h at 4 ºC. The eluted proteins were separated by 10 % SDS-PAGE and transferred to a nitrocellulose membrane for immunoblotting. The membranes were blocked with 5 % milk in TBS (10 mM Tris-HCl, pH 7.6, 150 mM NaCl) and incubated with their corresponding antibodies. A secondary antibody, provided by Amersham (NJ, USA), allowed the first antibody to be observed by enhanced chemiluminescence (ECL).
Interleukin-2 luciferase assay
Jurkat T-cells were co-transfected with 10 µg of corresponding cDNA and combined with 2 µg of pNFAT3-Luc plasmid or 0.1 µg of a control reporter plasmid (pRL-TK from Promega). Cells were pulsed using BTX Gene Pulser at 260 V, 960 F in 10 % Fetal Calf Serum. Cells (1 × 10 7 cells) were aliquoted in a 96-well plate 18 hrs after transfection and cultured in a final volume of 200 µL of RPMI 1640 growth medium. After 5 h stimulation by CD3 (145-2C11; 2 µg/mL), CD3/rabbit anti-mouse (2 µg/mL) antibodies, or rabbit anti-mouse antibodies alone (which served as negative controls), cells were lysed in 100 µL of lysis buffer (Promega kit, Promega, WI, USA). Luciferase activity was quantified using a luminometer (MicroLumat, EG7G Berthold) immediately after addition of 100 µL luciferase substrate (Promega kit) and a Stop and Go reaction to control amounts of reporter plasmid (dual luciferase system kit from Promega, WI, USA). Luciferase units of the experimental vector were normalized to the level of the control vector in each sample.
Statistical analysis
Data are presented as mean ± SEM (n = 3). Statistical analysis was performed with a statistical software (SAS Institute, Cray, NC, USA) using one-way analysis of variance, followed by Dunnett's multiple range tests. P < 0.05 was considered statistically significant. ANS. To assess which of these five tyrosines represent phosphorylation sites, we generated a series of SIT mutants.
RESULTS

Identification
To determine whether the tyrosine base motifs are sites of phosphorylation, wild-type SIT (WT SIT) and SIT mutants were expressed in Jurkat T cells, the cell were activated 2 min with pervanadate and were assessed for phosphorylation by anti-phosphotyrosine blotting (Fig. 1B, upper panel) 1C ). As an internal control for expression, anti-SIT Ab detected similar levels of expression for SIT and the mutants (Fig. 1B, lower ANS) were co-expressed with CTLA-4 in Jurkat T cells followed by immuno-precipitation with anti-CTLA Ab and anti-SIT blotting. The expression levels of SIT and the mutants and CTLA-4 were similar as shown in the whole-cell lysates ( Fig. 2A, right upper and (Fig 3) .
By contrast, the F 128 TSL and F 148 SEV had little effect on with CTLA-4. WT experiments showed no effect. This limited interaction may be sufficient to mediate the down-regulation of TCRstimulated NF-AT/AP-1 activity.
Analysis of the SIT mutants indicate that SIT-CTLA-4 interaction is crucial in the downregulation of T cell pathway, as a marked enhancing of NF-AT/AP-1 activity was observed in transfectants expressing the mutants compared with the WT FYB (Fig. 3) . Reported mechanisms include competition for CD28 binding to CD80 and CD86 [8] , disruption of CD28 localization at the immunological synapse [9] , binding to phosphatases PP2A and SHP-2 and interference with lipid raft expression [10] . In contrast to CD28, which is found on resting and activated cells, CTLA-4 is only found on activated cells. It is primarily an intracellular antigen whose surface expression is tightly regulated [11] . This tight regulation is achieved by controlled trafficking to the cell surface and rapid internalization. Even at its highest amounts, surface expression of CTLA-4 is only at about 3 percent of the time CD28 (the positive coreceptor) is expressed [12] .
During the past few years, several TRAPs involved in the relay signaling have been identified including LAT (linker for activation of Tcells), SIT (SHP2 interacting transmembrane adaptor protein), LAX (lck interacting membrane protein), LIME (lck interacting membrane protein), NTAL/LAB (T-cell activation linker/linker for activation of B-cells) and PAG/Cbp (phosphoprotein associated with glycosphingolipid-enriched microdomains/CSK binding protein) [13] .
Recently, the small transmembrane adaptor protein T cell receptorinteracting molecule (TRIM) was found to bind to CTLA-4 leading to enhanced CTLA-4 surface expression [7] .
SIT-R is capable of binding to CTLA-4 in T-cell. This identification of SIT binding to CTLA-4 increases the number of proteins known to bind CTLA-4, and possibly suggests that SIT and SIT-R will act in a negative signaling cascade. From our observations, it appears that in T cells both Tyr 148 and Tyr 188 are essential for optimal binding of CTLA-4.
The regulation of CTLA-4 function by interaction with SIT may serve as a possible accessory immunomodulatory molecule for optimizing T-cell function. In addition, the absence of CTLA-4 has been shown to result in organ destruction, lymphoproliferative disease and numerous autoimmune diseases in human including diabetes. On the contrary, an excessive decrease in T-cell mediated immune reaction by CTLA-4/SIT complex leads to chronic infection.
CONCLUSION
The findings of this study show that TRAP, termed SIT transmembrane adaptor (SIT) protein, binds to CTLA-4 and potentiates the inhibitory role of this co-receptor. SIT-R plays an important role in the functions of CTLA-4, and hence, extensive studies of its properties in vivo is required.
